The US Food and Drug Administration has begun reviewing FYB206, a proposed biosimilar to the cancer drug Keytruda developed ...

Zydus Lifesciences Limited (Zydus), an innovation-led global life-sciences company, and Formycon AG (Formycon), an ...

The US Food and Drug Administration has accepted a biologics license application for a proposed biosimilar to the cancer drug ...

KEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minute The approval of KEYJECT is based on ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...

The U.S. Food and Drug Administration has approved a new first-line treatment for people with pleural mesothelioma that can’t be removed with surgery. This new approval is specifically for a Keytruda ...

In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture ...

The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer. The recent approvalof ...

Keytruda generated $16.40 billion in sales in the first six months of 2026, increasing 4.2% year over year. Keytruda Qlex, ...

KEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)--Sep.